CCL2, a signaling protein that recruits immune cells to sites of injury, may play a key role in driving the nerve damage that results from antibodies against the aquaporin-4 (AQP4) protein in neuromyelitis optica spectrum disorder (NMOSD), a study suggests. The signaling protein was found to be elevated in…
nerve damage
A signaling molecule called CXCL7 drives inflammation and nerve fiber damage in a mouse model of neuromyelitis optica spectrum disorder (NMOSD), a new study reports. The findings show that this signaling molecule “is a key factor in the formation of lesions in the brain, spinal cord, and retina,” the…
People with neuromyelitis optica spectrum disorder (NMOSD), but lacking anti-AQP4 and anti-MOG antibodies, show no signs of damage to astrocytes — nervous system cells attacked in NMOSD — when compared to those with anti-AQP4 antibodies. Those findings from a recent study suggest that the mechanisms underlying NMOSD symptoms in…
One of the most difficult aspects for me of living with neuromyelitis optica (NMO) is dealing with chronic pain. It’s what most affects my quality of life, but in my opinion, it’s also the least addressed and treated issue. In 2012,…
Recent Posts
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD
- Advanced plasma exchange therapy effectively eases NMOSD attacks
- Reaffirming that access to healthcare is a human right
- Brain, spinal cord shrinkage linked to distinct NMOSD outcomes: Study
- Reflecting on what I’m grateful for softens the edges of NMOSD
- When my invisible illness meets my very visible disabled parking spot
- Study IDs environmental factors tied globally to higher NMOSD risk
- Inflammatory protein S100A9 ID’d as new treatment target in NMOSD
- Connecting with others who have NMOSD gave me hope